{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:10:25Z","timestamp":1772165425097,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Taiwan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregabalin is approved for the treatment of neuropathic pain, fibromyalgia, and seizure disorders, although the pivotal trials were mostly carried out in Europe or North America. The prescribing patterns among different indications in Asia have rarely been explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a population-based retrospective cohort study based on the National Health Insurance Research Database in Taiwan. Prescriptions of pregabalin were identified, and data regarding demographics, indications, co-existing diagnoses, and concomitant medications were extracted. Pregabalin users were followed for at least one year, and factors associated with persistence at one year were determined by using multivariate logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between June 2012 and December 2016, 114,437 pregabalin users (mean age 60.7\u2009\u00b1\u200915.4\u2009years, 57.8% female) were identified. The indications included post-herpetic neuralgia (PHN) (30.5%), musculoskeletal diseases other than fibromyalgia (21.2%), fibromyalgia (18.4%), diabetic peripheral neuropathic pain (DPNP) (11.7%) and epilepsy (2.9%). Overall, 62.5% and 6.4% of patients achieved a maximum dose of \u2265150 and\u00a0\u2265\u00a0300\u2009mg\/day, respectively. The median duration of persistent pregabalin use was 28\u2009days (interquartile range 14\u2013118\u2009days). The one-year persistence rate was 12.1%, and the indications associated with the highest and lowest persistence rates were epilepsy (42.4%) and PHN (6.1%), respectively. Male gender (odds ratio [OR] 1.14, 95% confidence interval [CI] 1.09\u20131.18), older age (OR 1.01 per year, 95% CI 1.01\u20131.01), indications other than PHN, especially epilepsy (OR 8.04, 95% CI 7.33\u20138.81, PHN as reference), and a higher initial dose (OR 1.12 per 75\u2009mg, 95% CI\u2009=\u20091.10\u20131.15) were associated with persistence at one year, whereas the initial concomitant use of antiviral agents decreased the likelihood (OR 0.41, 95% CI 0.35\u20130.47).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pregabalin prescriptions for pain disorders were limited to short-term use, which is consistent around the world. However, the average prescribed dose in Taiwan was lower than those in Western countries, and was frequently below the recommended ranges. Potential causes included the duration of natural history of PHN, and off-label prescriptions for pain in acute herpes zoster, rather than PHN, as well as intolerance to the side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-020-01123-4","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T03:03:49Z","timestamp":1589857429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yen-Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Tai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben-Chang","family":"Shia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-5358","authenticated-orcid":false,"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"issue":"11","key":"1123_CR1","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","volume":"16","author":"EP Calandre","year":"2016","unstructured":"Calandre EP, Rico-Villademoros F, Slim M (2016) Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 16(11):1263\u20131277","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"1123_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","volume":"132","author":"RH Dworkin","year":"2007","unstructured":"Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS et al (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132(3):237\u2013251","journal-title":"Pain"},{"issue":"2","key":"1123_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"3 Suppl","key":"1123_CR4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML et al (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(3 Suppl):S3\u2013S14","journal-title":"Mayo Clin Proc"},{"issue":"20","key":"1123_CR5","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","volume":"76","author":"V Bril","year":"2011","unstructured":"Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D et al (2011) Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of physical medicine and rehabilitation. Neurology. 76(20):1758\u20131765","journal-title":"Neurology."},{"issue":"6","key":"1123_CR6","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mus.22092","volume":"43","author":"V Bril","year":"2011","unstructured":"Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR et al (2011) Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve 43(6):910\u2013917","journal-title":"Muscle Nerve"},{"issue":"9","key":"1123_CR7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/14656566.2015.1047343","volume":"16","author":"EP Calandre","year":"2015","unstructured":"Calandre EP, Rico-Villademoros F, Slim M (2015) An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother 16(9):1347\u20131368","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1123_CR8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","volume":"76","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluss E et al (2017) EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 76(2):318\u2013328","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1123_CR9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00325481.2017.1336417","volume":"129","author":"LM Arnold","year":"2017","unstructured":"Arnold LM, Clauw DJ (2017) Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgrad Med 129(7):709\u2013714","journal-title":"Postgrad Med"},{"issue":"2","key":"1123_CR10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","volume":"91","author":"AM Kanner","year":"2018","unstructured":"Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF et al (2018) Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of neurology and the American Epilepsy Society. Neurology. 91(2):82\u201390","journal-title":"Neurology."},{"key":"1123_CR11","unstructured":"Pregabalin package insert (2019). https:\/\/info.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024995&Seq=015&Type=9."},{"issue":"10","key":"1123_CR12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/BF03261976","volume":"35","author":"S Ogawa","year":"2012","unstructured":"Ogawa S, Satoh J, Arakawa A, Yoshiyama T, Suzuki M (2012) Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf 35(10):793\u2013806","journal-title":"Drug Saf"},{"issue":"20","key":"1123_CR13","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/WNL.0000000000003882","volume":"88","author":"JM Waldfogel","year":"2017","unstructured":"Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM et al (2017) Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 88(20):1958\u20131967","journal-title":"Neurology."},{"issue":"4","key":"1123_CR14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/rheumatology\/kep432","volume":"49","author":"S Straube","year":"2010","unstructured":"Straube S, Derry S, Moore RA, McQuay HJ (2010) Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 49(4):706\u2013715","journal-title":"Rheumatology (Oxford)"},{"issue":"1\u20132","key":"1123_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","volume":"145","author":"W Hauser","year":"2009","unstructured":"Hauser W, Bernardy K, Uceyler N, Sommer C (2009) Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain 145(1\u20132):69\u201381","journal-title":"Pain"},{"issue":"1","key":"1123_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40261-012-0030-4","volume":"33","author":"P Johnson","year":"2013","unstructured":"Johnson P, Becker L, Halpern R, Sweeney M (2013) Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig 33(1):35\u201344","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1123_CR17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijcp.12182","volume":"68","author":"B Wettermark","year":"2014","unstructured":"Wettermark B, Brandt L, Kieler H, Boden R (2014) Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract 68(1):104\u2013110","journal-title":"Int J Clin Pract"},{"issue":"10","key":"1123_CR18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3899\/jrheum.170098","volume":"44","author":"D Ben-Ami Shor","year":"2017","unstructured":"Ben-Ami Shor D, Weitzman D, Dahan S, Gendelman O, Bar-On Y, Amital D et al (2017) Adherence and persistence with drug therapy among fibromyalgia patients: data from a large health maintenance organization. J Rheumatol 44(10):1499\u20131506","journal-title":"J Rheumatol"},{"issue":"16","key":"1123_CR19","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1080\/14656566.2019.1651840","volume":"20","author":"T Ushida","year":"2019","unstructured":"Ushida T, Matsui D, Inoue T, Yokoyama M, Takatsuna H, Matsumoto T et al (2019) Recent prescription status of oral analgesics in Japan in real-world clinical settings: retrospective study using a large-scale prescription database. Expert Opin Pharmacother 20(16):2041\u20132052","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"1123_CR20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1742-1241.2010.02389.x","volume":"64","author":"M Xochilcal-Morales","year":"2010","unstructured":"Xochilcal-Morales M, Castro EM, Guajardo-Rosas J, Obregon TN, Acevedo JC, Chucan JM et al (2010) A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. Int J Clin Pract 64(9):1301\u20131309","journal-title":"Int J Clin Pract"},{"issue":"6","key":"1123_CR21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/11589370-000000000-00000","volume":"31","author":"E Anastassiou","year":"2011","unstructured":"Anastassiou E, Iatrou CA, Vlaikidis N, Vafiadou M, Stamatiou G, Plesia E et al (2011) Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 31(6):417\u2013426","journal-title":"Clin Drug Investig."},{"issue":"2","key":"1123_CR22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","volume":"153","author":"D Bouhassira","year":"2012","unstructured":"Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C et al (2012) Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 153(2):342\u2013349","journal-title":"Pain"},{"issue":"6","key":"1123_CR23","first-page":"416","volume":"59","author":"MW McKendrick","year":"2009","unstructured":"McKendrick MW, Ogan P, Care CC (2009) A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. J Inf Secur 59(6):416\u2013420","journal-title":"J Inf Secur"},{"key":"1123_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1745-6215-12-55","volume":"12","author":"C Jensen-Dahm","year":"2011","unstructured":"Jensen-Dahm C, Rowbotham MC, Reda H, Petersen KL (2011) Effect of a single dose of pregabalin on herpes zoster pain. Trials. 12:55","journal-title":"Trials."},{"issue":"4","key":"1123_CR25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5214\/ans.0972.7531.1118405","volume":"18","author":"SK Kanodia","year":"2011","unstructured":"Kanodia SK, Singhal KC (2011) A study on efficacy of Pregabalin in acute herpetic neuralgia. Ann Neurosci 18(4):148\u2013150","journal-title":"Ann Neurosci"},{"key":"1123_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yebeh.2018.05.019","volume":"85","author":"E Faught","year":"2018","unstructured":"Faught E, Helmers S, Thurman D, Kim H, Kalilani L (2018) Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: a US database analysis. Epilepsy Behav 85:37\u201344","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1123_CR27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jpepsy\/jsu010","volume":"40","author":"BS Aylward","year":"2015","unstructured":"Aylward BS, Rausch JR, Modi AC (2015) An examination of 1-year adherence and persistence rates to antiepileptic medication in children with newly diagnosed epilepsy. J Pediatr Psychol 40(1):66\u201374","journal-title":"J Pediatr Psychol"},{"issue":"4","key":"1123_CR28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/epd.2016.0871","volume":"18","author":"YK Lee","year":"2016","unstructured":"Lee YK, Ah YM, Choi YJ, Cho YS, Kim KJ, Lee JY (2016) Antiepileptic drug adherence and persistence in children with epilepsy attending a large tertiary care children's hospital. Epileptic Disord 18(4):408\u2013417","journal-title":"Epileptic Disord"},{"issue":"7","key":"1123_CR29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ejpain.2007.12.004","volume":"12","author":"R Baron","year":"2008","unstructured":"Baron R, Brunnmuller U, Brasser M, May M, Binder A (2008) Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain 12(7):850\u2013858","journal-title":"Eur J Pain"},{"key":"1123_CR30","first-page":"293","volume":"9","author":"ME Crawford","year":"2016","unstructured":"Crawford ME, Poulsen PB, Schiottz-Christensen B, Habicht A, Strand M, Bach FW (2016) Real-life efficacy of pregabalin for the treatment of peripheral neuropathic pain in daily clinical practice in Denmark: the NEP-TUNE study. J Pain Res 9:293\u2013302","journal-title":"J Pain Res"},{"issue":"1","key":"1123_CR31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2125.2011.03932.x","volume":"72","author":"S Shoji","year":"2011","unstructured":"Shoji S, Suzuki M, Tomono Y, Bockbrader HN, Matsui S (2011) Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol 72(1):63\u201376","journal-title":"Br J Clin Pharmacol"},{"issue":"19","key":"1123_CR32","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/CIRCULATIONAHA.114.012717","volume":"130","author":"CJ Shih","year":"2014","unstructured":"Shih CJ, Chu H, Chao PW, Lee YJ, Kuo SC, Li SY et al (2014) Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study. Circulation. 130(19):1684\u20131691","journal-title":"Circulation."},{"issue":"7","key":"1123_CR33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ajg.2017.101","volume":"112","author":"YF Wang","year":"2017","unstructured":"Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ (2017) Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a Nationwide population-based study. Am J Gastroenterol 112(7):1084\u20131093","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1123_CR34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0333102416642602","volume":"37","author":"KP Peng","year":"2017","unstructured":"Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ (2017) Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia 37(4):327\u2013335","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01123-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01123-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01123-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T19:16:54Z","timestamp":1621365414000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01123-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01123-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-18478\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-18478\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"21 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocols were approved by the Institutional Review Board of National Yang-Ming University (approval No. YM105009E).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YFW has received honoraria as a speaker from Taiwan branches of Allergan, Pfizer, Eli Lilly, Novartis, and Sanofi. He has received research grants from the Taiwan Minister of Technology and Science, and Taipei Veterans General Hospital.SJW has served on the advisory boards of Eli Lilly, Daiichi-Sankyo, and Taiwan Novartis. He has received honoraria as a moderator from Allergan, Pfizer, Eli Lilly, Bayer, and Eisai. He has received research grants from the Taiwan Minister of Technology and Science, National Yang-Ming University, Taipei Veterans General Hospital, Taiwan Headache Society, Taiwan Pfizer, Taiwan Novartis, and Taiwan Eli Lilly. CWT, YCY, YCC, and BCS declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}